Clinical trial · Interventional
Clinical Trial of TQB3002 in Patients With Advanced Cancers
A Phase I Clinical Study of TQB3002 in Patients With Advanced Cancers
NCT06662760CI-TRIAL-00097908recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TQB3002 Tablets | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TQB3002 Tablets
- description
- TQB3002 Tablets, 28 days as a treatment cycle
- interventionNames
- Drug: TQB3002 Tablets
Primary outcomes (2)
- measure
- Dose Limiting Toxicity (DLT)
- timeFrame
- During the first 28 days
- description
- DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred within the first cycle(28days) of treatment.
- measure
- Maximum tolerated dose (MTD)
- timeFrame
- During the first 28 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects voluntarily joined this study, signed the informed consent form, and had good compliance； * Age: ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months； * Histologically or cytologically diagnosed with advanced cancers * Subjects with advanced malignancies who have failed standard therapy or lack effective treatment * Major organs are functioning well； * Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study. Exclusion Criteria: * Current concomitant presence of other malignancies within 5 years prior to the first dose； * Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy * Significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose * Long-term unhealed wounds or fractures * Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose * Swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy * A history of psychotropic drug abuse and cannot be abstained from or have a mental disorder * Subjects with any severe and/or uncontrolled disease
References
Publications (0)
Data not yet available
No reference posted for this study.